Formula Pharmaceuticals, Inc. is a privately-held, oncology focused company developing unique Chimeric Antigen Receptor (“CAR”) immunotherapies to address critical unmet medical needs in cancer. Distinctive from existing CAR-T approaches, Formula leverages an ALLOGENEIC source, NON-viral tranfection and a differentiated immune effector cell, called Cytokine Induced Killer (C.I.K.) cell. Formula has assembled a world-class scientific, clinical development and business team well positioned to maximize the clinical and commercial value of promising drug candidates through excellence in drug development and strategic partnering.